Analgesic Efficacy of Serratus Posterior Superior Intercostal Plane (SPSIP) Block in Shoulder Arthroscopies

Launched by KANUNI SULTAN SULEYMAN TRAINING AND RESEARCH HOSPITAL · May 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a specific pain relief technique called the Serratus Posterior Superior Intercostal Plane (SPSIP) block for patients undergoing shoulder arthroscopy surgery. The goal is to see if this method can help reduce pain after surgery compared to standard pain management. Participants in the trial will be placed in a comfortable position before they wake up from surgery, and a special ultrasound will be used to guide the placement of the block, which involves injecting a numbing medication. Both groups of patients will receive additional pain relief medications after their surgery.

To be eligible for the trial, participants must be between 18 and 65 years old, have a good overall health status (ASA score of I-II), and not have certain medical conditions that could complicate the procedure, such as bleeding disorders or neuropathic diseases like diabetes. Throughout the trial, patients will be monitored closely for their pain levels at various times after surgery and will have access to pain relief options as needed. This study aims to improve post-surgery pain management for those undergoing shoulder procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Obtaining consent from the patient and their relative
• • ASA score of I-II
• • No bleeding diathesis
• • No history of anticoagulant use
• • No history of neuropathic diseases such as Diabetes Mellitus
• • Patients aged 18-65 years undergoing shoulder arthroscopy surgery
• Exclusion Criteria:
• • Lack of consent from the patient or their relative
• • Patients with an ASA score of III or above
• • Patients with a history of bleeding diathesis
• • Conditions where regional anesthesia is contraindicated
• • Patients with a history of neuropathic diseases
• • Patients under 18 years or over 65 years of age
• • Patients with a history of allergies to the aforementioned medications
• • Patients with an infection at the site where the block will be administered

Trial Officials